INOZYME PHARMA INC. -

Inozyme Pharma to Present at the H.C. Wainwright 25th Annual Global Investment Conference

05 Sep 2023 07:30:00 By Nasdaq GlobeNewswire

Inozyme Pharma Reports Second Quarter 2023 Financial Results and Provides Business Highlights

08 Aug 2023 07:30:00 By Nasdaq GlobeNewswire

Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

03 Aug 2023 15:01:00 By Nasdaq GlobeNewswire

Inozyme Pharma, Inc. Announces Closing of Public Offering of Common Stock

01 Aug 2023 15:01:00 By Nasdaq GlobeNewswire

Inozyme Pharma, Inc. Announces Pricing of Public Offering of Common Stock

27 Jul 2023 22:20:15 By Nasdaq GlobeNewswire

Inozyme Pharma, Inc. Announces Proposed Offering of Common Stock

27 Jul 2023 15:33:08 By Nasdaq GlobeNewswire

Inozyme Pharma Announces Updates on Global Development Strategy of INZ-701 for the Treatment of ENPP1 Deficiency

26 Jul 2023 06:30:00 By Nasdaq GlobeNewswire

Inozyme Pharma to Provide ENPP1 Deficiency Program Update on July 26, 2023

19 Jul 2023 07:30:00 By Nasdaq GlobeNewswire

Inozyme Pharma Announces Dosing of First Infant with ENPP1 Deficiency in a Phase 1b Trial of INZ-701

27 Jun 2023 07:30:00 By Nasdaq GlobeNewswire

Inozyme Pharma to Present at the Jefferies Healthcare Conference

02 Jun 2023 06:30:00 By Nasdaq GlobeNewswire

Inozyme Pharma Reports First Quarter 2023 Financial Results and Provides Business Highlights

09 May 2023 07:30:00 By Nasdaq GlobeNewswire

Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

03 May 2023 07:30:00 By Nasdaq GlobeNewswire

Inozyme Pharma to Present Recently Announced Preliminary Data from Ongoing Phase 1/2 Trial in ENPP1 Deficiency at the European Calcified Tissue Society Congress (ECTS)

14 Apr 2023 07:30:00 By Nasdaq GlobeNewswire

Inozyme Pharma to Participate at the 22nd Annual Needham Virtual Healthcare Conference

11 Apr 2023 07:30:00 By Nasdaq GlobeNewswire

Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Operations Officer

04 Apr 2023 07:30:00 By Nasdaq GlobeNewswire

Inozyme Pharma Reports Full Year 2022 Financial Results and Provides Business Highlights

22 Mar 2023 07:30:00 By Nasdaq GlobeNewswire

Inozyme Pharma to Participate in the Cowen 43rd Annual Health Care Conference

01 Mar 2023 07:30:00 By Nasdaq GlobeNewswire

Inozyme Pharma Reports Positive Topline Data from Ongoing Phase 1/2 Trials of INZ-701

16 Feb 2023 06:30:00 By Nasdaq GlobeNewswire

Inozyme Pharma to Host Virtual Investor and Analyst Event on Feb. 16, 2023

06 Feb 2023 06:30:00 By Nasdaq GlobeNewswire

Inozyme Pharma Announces Investor and Analyst Event and Highlights 2022 Progress

09 Jan 2023 07:30:00 By Nasdaq GlobeNewswire